ESC Premium Access

Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

Congress Presentation

About the speaker

Doctor Thomas Vanassche

University Hospitals (UZ) Leuven, Leuven (Belgium)
2 presentations
0 follower

4 more presentations in this session

Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis

Speaker: Mr A. Roddick (Oxford, GB)


Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

Speaker: Miss O. Ghosh-Swaby (London, CA)


Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy

Speaker: Professor M. Roe (Chapel Hill, US)


Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

Speaker: Doctor R. Diaz (Rosario, AR)


Access the full session

Progress in secondary prevention - New treatments

Speakers: Doctor T. Vanassche, Mr A. Roddick, Miss O. Ghosh-Swaby, Professor M. Roe, Doctor R. Diaz

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb